Application of ganoderic acid A in preparation of medicine for preventing and/or treating renal injury caused by shock

• Main Authors: ZENG YE, XIE LINSHEN, OUYANG ZHI, SHEN JUNYI, WANG SIWEN, ZHONG JIAN, CHEN MENGLIN, LI ZHONG, JIANG WENLI, QIU YAN, JIN QIAOLING, LI YAXIN
• Format: Patent
• Language: Chinese; English
• Published: 22.12.2023
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention discloses an application of ganoderic acid A in preparation of a medicine for preventing and/or treating renal injury caused by shock. The ganoderic acid A can significantly reduce expression of RNA and protein of HIF-1alpha in an oxygen-glucose deprivation/rehydration (OGD/R) model, and can reduce HK-2 cell OGD/R damage through an HIF-1alpha-mediated related pathway. In addition, under the oxygen-glucose deprivation/complex glucose reoxygenation condition, the ganoderic acid A also has a better removal effect on ROS and has a better protection effect on the body. Besides, compared with a normal group, the acute kidney injury group has the advantages that inflammatory cell infiltration, renal tubule swelling, obvious disorder of cell nucleus arrangement, glomerular degeneration, severe edema of renal interstitial substance and formation of swelling necrosis degeneration are reduced, and after ganoderic acid A treatment, inflammatory cell infiltration is reduced, renal tubule swelling is reduced,